Adcock Ingram Holdings Ltd
JSE:AIP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adcock Ingram Holdings Ltd
Stock-Based Compensation
Adcock Ingram Holdings Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Adcock Ingram Holdings Ltd
JSE:AIP
|
Stock-Based Compensation
38.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
110%
|
CAGR 10-Years
10%
|
|
|
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Ascendis Health Ltd
JSE:ASC
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Adcock Ingram Holdings Ltd
Glance View
Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.
See Also
What is Adcock Ingram Holdings Ltd's Stock-Based Compensation?
Stock-Based Compensation
38.1m
ZAR
Based on the financial report for Jun 30, 2025, Adcock Ingram Holdings Ltd's Stock-Based Compensation amounts to 38.1m ZAR.
What is Adcock Ingram Holdings Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
10%
Over the last year, the Stock-Based Compensation growth was -15%. The average annual Stock-Based Compensation growth rates for Adcock Ingram Holdings Ltd have been -2% over the past three years , 110% over the past five years , and 10% over the past ten years .